Tag Archives: Director Iancu

Rejected, With a Road Map: Allowable Subject Matter in the First Action

Two important patent prosecution data points that are in tension:

  • The vast majority of patent applications are initially rejected by the patent examiner; and
  • The vast majority of patent applications eventually issue as a patent.

I'm wanting to dig in further into the process of "getting to yes" and understand keys to success.

About 14% of first actions on the merits (FAOMs) are notices of allowance. That is the blue line in the chart above -- and that fits my idea that nearly everyone gets rejected  initially.   But the orange line adds new information -- those add in actions that reject claims, but told the applicant that something in the case was already allowable. That line sits near 40%.  In other words, in about 40% of cases, the first offer (the initial claim set) is at least partially accepted.

The chart above shows a 3-month moving average -- there are pretty dramatic swings in rates on both bi-week and monthly bases.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

The Real-Time View: USPTO Allowance Rate “Dips” to 75%

by Dennis Crouch

In February 2026, I published a study tracking the patent allowance rate by filing-date cohort, following every published utility application from filing to final resolution. See Dennis Crouch, The 20-Year Allowance Rate Arc, Patently-O (Feb. 27, 2026). That approach answer backward-looking question: of all the applications filed in a given month, what share ultimately became patents.  It is the right metric for understanding how the patent system treats a generation of filings, but it carries an inherent delay. An application filed in 2020 does not resolve for two to four years, meaning the cohort data tells us about examination culture circa 2022-2024, not about what the agency is doing right now.

Today I want to offer a complementary view. Instead of grouping applications by when they were filed, the chart below groups them by when they were resolved. Each data point represents the percentage of applications disposed of in a given month (either issued as patents or abandoned) that resulted in issued patents. I call this the "disposal allowance rate," and it functions as a more immediate signal of the agency's examination posture.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

The 20-Year Allowance Rate Arc: From Trough to Peak and Back Again

by Dennis Crouch

Every patent application eventually resolves into one of two outcomes: it issues as a patent or it is abandoned. I have been tracking those outcomes (along with those applications "still pending") for every published utility application filed at the USPTO over the past two decades - and see some striking patterns. The patent allowance rate, measured as the percentage of resolved applications that issued as patents, traces a deep V-curve across two decades. Applications filed in 2001 had an allowance rate of about 71%. That figure dropped steadily to a trough of 59% for applications filed in May 2006. It then reversed course and climbed, year after year, through 67% in 2010, 74% in 2015, and up to 82% for those filed in early 2020. That is a 23-percentage-point swing from trough to peak.

The first chart below plots the allowance rate by filing month for all published U.S. utility patent applications filed between January 2001 and July 2024. The allowance rate is calculated as the number of applications that issued as patents divided by the number that have been resolved (issued plus abandoned), excluding applications that remain pending. For cohorts filed before late 2021, fewer than 10% of applications remain pending, making the data highly reliable. For more recent filing months, the dashed line reflects preliminary data that will almost certainly shift (downward) as the remaining applications resolve.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

PERA 2025: Eligibility Reform Returns to Capitol Hill

by Dennis Crouch

On October 8, 2025, the Senate Judiciary Subcommittee on Intellectual Property held a hearing on the Patent Eligibility Restoration Act (PERA) of 2025 (S. 1546), legislation that would fundamentally reshape 35 U.S.C. § 101 and effectively overturn the Supreme Court's Mayo, Myriad, and Alice decisions.  The hearing featured testimony from former USPTO Directors Andrei Iancu and David Kappos, China IP expert Mark Cohen, biotech executives, patient advocates, and retail industry representatives, all addressing whether Congress should replace the judge-made "abstract idea" and "law of nature" exceptions with a set of narrow statutory exclusions. Chairman Thom Tillis (R-NC) and ranking member Adam Schiff (D-CA) both acknowledged the widespread confusion in current eligibility jurisprudence, with Tillis noting that the status quo "continues to be hopelessly confused" and expressing determination to move the bill forward to committee markup. The Bill has bipartisan support in the Senate, but it is unclear  how hard those in opposition would push if the bill started to move forward.

PERA was originally introduced back in 2019 as a draft proposal. It was later reintroduced as S.4734 in 2022 and has been refined through successive versions, with the current 2025 bill (S.1546) representing a more measured approach than earlier drafts while still fundamentally overhauling § 101. The 2019 proposal included explicit language stating that all judicially created exceptions were "hereby abrogated." Later versions achieve the same result more subtly by specifying that eligibility is determined "subject only to" the enumerated statutory exclusions. The 2022 version would have made isolated human genes patent-eligible, directly contradicting Myriad's core holding, but the 2025 bill narrows this by removing "isolated" from the human gene provision—meaning mere isolation of natural DNA wouldn't suffice for eligibility, though purified, modified, or engineered genes used in inventions would still qualify. Similarly, where the 2022 draft used the ambiguous term "non-technological" to define excluded business methods, the 2025 version asks whether the machine is "necessary to practically perform" the invention. Probably most importantly, the 2025 bill adds new guardrails against patenting superficial computerization of otherwise abstract ideas.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Welcome USPTO Director Coke Morgan Stewart

by Dennis Crouch

Just after President Trump spoke the oath of office, Coke Morgan Stewart was also sworn in as Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the USPTO on January 20, 2025. She is serving as Acting Director. The previous Director, Kathi Vidal, departed to Winston & Strawn in December, and Deputy Director Derrick Brent, who had been serving in an interim capacity, has also now resigned. Commissioner Vaishali Udupa is remaining in her position for now as is Commissioner Gooder.

Welcome Director Stewart.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Commenting on the USPTO’s Proposed Rule on Terminal Disclaimers

[I have substantially updated this post - correcting a couple of issues from the original and also added info from the letter from former USPTO leaders. - DC 6/1/24]

by Dennis Crouch

As I have previously discussed on Patently-O, the USPTO recently issued a notice of proposed rulemaking that could significantly impact patent practice, particularly in the realm of terminal disclaimers filed to overcome non-statutory double patenting rejections. Dennis Crouch, Major Proposed Changes to Terminal Disclaimer Practice (and You are Not Going to Like it), Patently-O (May 9, 2024).  Under the proposed rule, a terminal disclaimer will only be accepted by the USPTO if it includes an agreement that the patent will be unenforceable if tied (directly or indirectly) to another patent that has any claim invalidated or canceled based on prior art (anticipation or obviousness under 35 U.S.C. 102 or 103). This proposal has generated significant debate among patent practitioners, with many expressing concerns about its potential impact on innovation and patent rights.  It is a dramatic change in practice because the typical rule required by statute is that the validity of each patent claim must be separately adjudged. See 35 U.S.C. § 282(a).

The comment period is open until early July, but a number of comments have already been submitted. And I looked through them in order to get some early feedback.  You can read the comments here


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.